Search

 
 
 

CELGENE ON BIOTECH HUNT WITH AGIOS, JOUNCE IN CROSSHAIRS: FT

After a tough few months for the Big Biotech, sources are telling the Financial Times that Celgene is looking to buy out some biotech...

 
 
 
Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

BIO ROUNDUP: BIOTECH IPOS, MIGRAINE PROGRESS, TAKEDA WOOS SHIRE & MORE

If the recent IPO activity seems to be on overdrive, it's not your imagination. The number of companies filing to go public in the...

Arena Pharma's Revamp Gains Traction With New Data For GI Drug

ARENA PHARMA'S REVAMP GAINS TRACTION WITH NEW DATA FOR GI DRUG

Arena Pharamceuticals' plan to reshape itself is advancing with new data for an ulcerative colitis drug that could pose a threat to...

 
 
 
Vividion Lands $101M from Celgene to Develop Protein-Targeting Drugs

VIVIDION LANDS $101M FROM CELGENE TO DEVELOP PROTEIN-TARGETING DRUGS

Vividion Therapeutics is partnering with Celgene to develop new drugs that modulate protein levels as a way of treating disease. Celgene...

 
 
 
Bio Roundup: Trump's Budget, Biogen's AD Reveal, Hugin's Run & More

BIO ROUNDUP: TRUMP'S BUDGET, BIOGEN'S AD REVEAL, HUGIN'S RUN & MORE

Another week of White House chaos and American gun violence. Amid it all, we tried to parse what the Trump administration's 2019 budget...

Bio Roundup: Trump's Budget, Biogen's AD Reveal, Hugin's Run & More

BIO ROUNDUP: TRUMP'S BUDGET, BIOGEN'S AD REVEAL, HUGIN'S RUN & MORE

Another week of White House chaos and American gun violence. Amid it all, we tried to parse what the Trump administration's 2019 budget...

 
 
 
Celularity Raises $250M to Make Stem Cell Treatments for Cancer & More

CELULARITY RAISES $250M TO MAKE STEM CELL TREATMENTS FOR CANCER & MORE

The placenta provides a fetus all of the nourishment it needs to grow and remain healthy. Executives at biotech startup Celularity...

Anatomy of two biotech deals worth $20B

ANATOMY OF TWO BIOTECH DEALS WORTH $20B

Analysts had forecast a blockbuster year for life science M&As, with the tax reforms taking effect and Big Pharma scrambling for late-stage...

 
 
 
WALL STREET PAYDAY: 4 banks made a killing from Monday's $20 billion in biotech deals

WALL STREET PAYDAY: 4 BANKS MADE A KILLING FROM MONDAY'S $20 BILLION IN BIOTECH DEALS

Biotech mergers and acquisitions are off to a hot start in 2018. On Monday, French drugmaker Sanofi spent $11.6 billion to buy US hemophilia...

Two drug companies are exploding after a pair of biotech mega-deals

TWO DRUG COMPANIES ARE EXPLODING AFTER A PAIR OF BIOTECH MEGA-DEALS

Markets Insider French drugmaker Sanofi is acquiring biotech company Bioverativ in a $11.6 billion deal. Celgene is acquiring Juno...

 
 
 
Celgene is buying cancer drugmaker Juno Therapeutics for $9 billion

CELGENE IS BUYING CANCER DRUGMAKER JUNO THERAPEUTICS FOR $9 BILLION

Celgene is acquiring Juno Therapeutics, a company developing personalized cancer treatments in a deal worth $9 billion. It's the second...

 
 
 

CELGENE SCOOPS UP SAN DIEGO BIOTECH IN $7B DEAL

The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.

J.P. MORGAN KICKS OFF WITH A DEAL AS CELGENE PAYS $1.1B FOR IMPACT BIOMEDICINES

On the first day of the big biotech conference that is J.P. Morgan, Celgene has come right out on day one with M&A news.

 
 
 

AFTER 2ND BET ON FAMILIAR DRUG, IMPACT BIO LANDS $1B CELGENE BUYOUT

Celgene has kicked off J.P. Morgan week-the annual healthcare investment gathering in San Francisco-with a blockbuster deal, acquiring...

DEVELOPING A SANOFI CAST-OFF, IMPACT BIOMEDICINES NOW SUBJECT OF RUMORED $7B CELGENE ACQUISITION DEAL

A startup developing the once-discarded fedratinib, a drug cast off from Sanofi due to safety concerns back in 2013, is now the subject...